Genmab

	18/11 21:52 af Bulder	Her Hutchings orale (link)
	18/11 21:40 af E L	;-)
	18/11 21:31 af Solsen	Find some epco abstracts....
	18/11 21:31 af Solsen	More hacking by you EL ;-)
	18/11 21:22 af E L	I am just way ahead of my time @Darvin :-D
	18/11 21:02 af Helge Larsen/PI-redaktør	Genmab @Genmab · 1 t #ICYMI – @WHO recently launched a global strategy to eliminate #cervicalcancer, it outlines three key steps: vaccination, screening and treatment. Learn more about the commitment by 194 countries to eliminate cervical cancer.(link)
	18/11 20:55 af Darvin	but ok - ASH is 5-7 dec ;-)
	18/11 20:53 af Helge Larsen/PI-redaktør	Lige nu søger markedsdeltagerne bare til noget som de tror/mener er bedre end det de har. Mange af dem har pharma. Det forlader de måske helt eller delvist i en periode, men vender så tilbage igen.
	18/11 20:53 af Darvin	EL - 17.19 - strange but your link gives an article dated 7 December 2020 :-)
	18/11 20:51 af Helge Larsen/PI-redaktør	Det er bare et gæt Klarussen.
	18/11 20:24 af Klarussen	Stoxx: Nu skal de europæiske healthcare aktier holde stand, ellers ….
	18/11 20:24 af Klarussen	(link)
	18/11 18:19 af E L	Novo Q3 "Regarding the FVIII-mimicking antibody project, Mim8, we have despite a COVID-19 related period of delay in phase 1, caught up with the timelines and are now in phase 2 in hemophilia patients with or without inhibitors, hemophilia A patients."
	18/11 18:19 af E L	Blood - A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys (link)
	18/11 18:14 af AaBforever	Pas nu på du ikke bare venter på Godot..;-)
	18/11 17:55 af Klarussen	@StockBull, ja, spændende om det er herfra vi skal opad på retracement. Holder nu krudtet tørt indtil videre.
	18/11 15:50 af StockBull	Wall street targets (link)
	18/11 15:20 af E L	the new kid on the block with a new Ph2 trial -A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (link)
	18/11 14:06 af Helge Larsen/PI-redaktør	We are pleased to share our financial calendar for 2021. For details, visit (link)
	18/11 13:29 af E L	Jan said he had a fireside chat toghether with JNJ's Paul Stoffels 2 days ago, has anyone seen that?
	18/11 13:27 af Solsen	Hope so :-)
	18/11 13:20 af E L	if they still see sufficient potential, such a partnership could be an elegant solution. We'll find out soon...
	18/11 13:14 af Solsen	All points at a dead candidate in Enapotamab, I belive.
	18/11 13:11 af E L	they also made me think about Enapotamab again , it has the same warhead as Tisotumab, i wonder if it could be a candidate for another 50:50 with Seagen. They already get a royalty.

	18/11 13:09 af E L	yes, it seems ASH could be more interesting as i had anticipated if they can reveal enough data on epco...
	18/11 13:05 af Solsen	He also said that the big epco ph 1/2 trial were inrolling in many cohort/indications which could lead to accelerated approval....
	18/11 12:58 af E L	Jan mentioned 5 Epco trials, where i only see 4, not sure if that was an error or we should see one very soon?
	18/11 12:57 af E L	of which they did not speak negatively by the way, Cami came up as another potential future revenue
	18/11 12:56 af E L	i thought it was interesting to hear Jan speak about AbbVie and also their next generation ADC technology. Wondering if we should put this in context with their decision on ADCT/ Cami T
	18/11 12:53 af E L	@Solsen isn't that what Judith said in the Q3? "s you see in the expansions, we are enrolling patients that are naive to checkpoint inhibitors in those tumors where the activity for PD-1s or PD-L1s is more sort of low. And in addition, we are enrolling like type tumor types that failed PD-1s, PD-L1s."
	18/11 12:43 af E L	so we learned that that there were 2 more cohorts with undisclosed target in the CMD; a guess could be ovarian and colorectal, as they actually tried a relatively high # of patients in the PhI? And yesterday he said the # is even higher as 9
	18/11 12:43 af Solsen	The most impressive is that JW said yesterday that they are selecting cancer indications which are known as not responders to PD-/PD-L1 drugs.
	18/11 12:39 af Bulder	2 more than in the Biontech slides. Do you know what indications?
	18/11 12:03 af E L	so those 9 expansion cohorts on GEN1046 aren't everything; that number is still going up...
	18/11 11:17 af Darvin	Tror meget vel du kan have ret StockBull, selv om det så skal gå rigtig godt!! ikke mindst - fordi - pipelinen formentlig performer mere end den skuffer. Men - det vil så også være en overordentlig god forrentning. 2.600 1 Jan er trods alt 14-15% fra nu og 3.000 1 dec 2021 er ca 32%. Lad det bare komme - julegaverne :-D
	18/11 11:10 af AaBforever	Det kommer vel an på om pipelinen performer?
	18/11 10:52 af StockBull	Selveste Warran E Buffet køber op i Big Pharma og mon ikke han analysearbejdet iorden. Genmab burde kunne rykker over kurs 3000 i 2021 så entry på nuværende niveau kan ikke gå helt galt
	18/11 10:49 af StockBull	Gætter på kurs ca. 2600 inden 1 Januar 2021
	18/11 10:47 af StockBull	Kan også være påvirket af sektorrotation. Tror den køre vidre op kommende 6-8 uger men man ved aldrig hvornår festen slutter.
	18/11 10:43 af Vitus	Ja, det kan nok godt blive svært at hale den i land til kurs 2150......
	18/11 10:38 af StockBull	Ser ud som normal TA. Ligner sidste 1.5år handels mønster
	18/11 10:31 af MarsFars	Skal ikke være pessimist, men den har de sidste mange dage lavet samme finte med at stige godt om formiddagen og så gå i minus sidst på dagen....
	18/11 08:25 af bibob	God morgen :-)
	18/11 07:17 af Helge Larsen/PI-redaktør	God morgen. :-)
	18/11 06:10 af StockBull	Morn :-) Ser ud til retracement er ved at være overstået. Spændende om vi bliver i kanalen eller den bryden nedad for evt. test af de berømte 2148 igen igen. Normalt stiger Genmab 350-400 point efter en så dyb retracement. Bliver godt nok spændende, at se hvad der sker kommende uger. (link)
	17/11 23:32 af GeorgeBest	(link)
	17/11 23:32 af GeorgeBest	Watch a video featuring Kate Sasser, corporate vice president on how our R&D centers at Utrecht, the Netherlands and Princeton, New Jersey drive the science forward to create therapies that have the potential to transform cancer treatment.
	17/11 21:54 af Optimistus	Ser ud til at Horizon får stoppet den seneste uges nedtur i dag, lad os håbe det smitter af på Genmab i morgen :-)
	17/11 21:08 af JørgenVarnæs	Det er skam heller ikke relevant - blot underholdende
	17/11 19:42 af Sukkeralf	AXL blev vel overhoved ikke nævnt idagens præsentation - og stort set alt andet, så den må toppe kisten over truede kandidater